Trial Profile
Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Rivastigmine (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- 19 Mar 2012 Actual end date Mar 2012 added as reported by ClinicalTrials.gov.
- 19 Mar 2012 Actual initiation date changed from Jun 2010 to Jul 2010 as reported by ClinicalTrials.gov.
- 19 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.